Clearpoint Neuro Inc. · NASDAQ:CLPT
Clearpoint Neuro — MRI Interventions — Investor Presentation (September 2018)
23 slides from Clearpoint Neuro's investor presentation, Sep 27, 2018
Slide 1: Investor Presentation
Investor Presentation Joe Burnett, President & CEO June 2018
Slide 2: Forward Looking Statements
Forward Looking Statements Statements herein concerning MRI Interventions, Inc. (the “Company”) plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance
Slide 3: Only a Fraction of Patients with Debilitating Neurological Disorders are Treated Surgically
Only a Fraction of Patients with Debilitating Neurological Disorders are being Treated Surgically Today… Prevalence of Neurological Disorders Parkinson's Epilepsy Tumor ICH Surgical Procedures Note: Prevalence numbers are based on either market research conducted by a third party on behalf of MRI In
Slide 4: The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body
The Movement to Minimally Invasive Procedures has Happened Everywhere Else in the Body… This transition has always had two things in common; 1. More patients being treated 2. Procedures are ENABLED BY LIVE IMAGE GUIDANCE
Slide 5: Traditional Stereotactic Neurosurgery is Limited
Traditional Stereotactic Neurosurgery is Limited Primary Challenge: The Skull in not ‘See Through’ 1. X-Ray and CT do not show structures of the brain 2. Large, Metallic Navigation Frames are not compatible inside an MRI Magnet
Slide 6: Our Solution: ClearPoint Neuro Navigation System Platform
Our Solution: ClearPoint® Neuro Navigation System Platform The only Neuro-Navigation System with ‘Sub-millimeter’ Accuracy ClearPoint Procedure Overview: ClearPoint Video Entry and Trajectory ClearPoint Video Alignment and Insertion
Slide 7: Our Value: We Decide, Guide & Confirm
Our Value: We DECIDE, GUIDE & CONFIRM the most challenging neurosurgery therapies Decide 1 Advanced Planning Software and Fusion Algorithms enable ‘Fly Through’ entry point and trajectory planning the day of the procedure using live MRI Images Guide 2 Uniquely enable changes to trajectory live, in t
Slide 8: MRIC: The Premier Company for Precision MRI-Guided Therapy
MRIC: The Premier Company for Precision MRI-Guided Therapy • MRI Interventions: Leader in Precision MRI-Guided Therapy • Unique Platform that allows delivery of therapies to the brain with pinpoint accuracy under live MRI Guidance • Entire procedure can take place in the MRI suite, reducing the risk
Slide 9: MRIC: A Proven Platform
MRIC: A Proven Platform MRI Interventions, Inc.: Headquarters: Irvine, CA Employees: 39 (16 Sales, 14 Product Dev.) 2017 Revenue: $7.4 Million Market Cap: $23 Million Cash: $7.5 million Gross margin: 63.7% Financial data as of March 31, 2018 quarter end Share data as of June 1, 2018 Key Products: Cl
Slide 10: Broad and Growing User Base of Leading Neurosurgeons
Broad and Growing User Base of Leading Neurosurgeons ClearPoint Is Installed in 53 Top US Hospitals and Growing UC San Francisco San Francisco VA Stanford Univ UCSF Benioff Childrens USC UC San Diego Univ of Colo Univ of Utah Univ of Arizona Cook Children’s MD Anderson Methodist Hosp Texas Children’
Slide 11: Our MRI-Guided Therapy Platform is Currently Being Used to
Our MRI-Guided Therapy Platform is Currently Being Used to: Implant Neuro Stimulation Leads from: Medtronic • St. Jude Medical • Boston Scientific • NeuroPace Place Laser Ablation Probes from: • Medtronic-Visualase • Monteris Medical MRIC Platform Runs on All Major Scanners: • Siemens • GE • Philips
Slide 12: Market Potential for Procedures
Market Potential for Procedures MRIC Growth Cntribution New Therapy Product Sales Direct & Though Partnerships ClearPoint & Caths in Drug Therapy Trials & Commercial Strategic & Focused Expansion to new geographies either direct or through partners 2+ Therapy Products & Opportunities to Distribute (
Slide 13: Electrode Placement and Laser Catheter Placement: Key Strategies for 2018
Electrode Placement for Deep Brain Stimulation Laser Catheter Placement for Ablation Procedures Key Strategies & Tactics for 2018: • Add 8-10 new centers from existing funnel via capital sales and evaluation agreements • Publish ‘Best Practices’ workflows to get procedures predictably under four hou
Slide 14: ClearPoint 2.0 Image Fusion Feature (Pending FDA Clearance)
ClearPoint 2.0 Image Fusion Feature (Pending FDA Clearance) Designed to reduce procedure time by fusing pre-procedure planning to real-time MRI imaging
Slide 15: Precise, Quantifiable Drug Delivery ClearPoint 2.0 Software
Precise, Quantifiable Drug Delivery ClearPoint 2.0 Software (Pending FDA Clearance) Key Strategies & Tactics for 2018: • Assign a ‘Sales Portfolio Manager’ to proactively build our brand as the premier partner in biologics and drug delivery to the brain • Launch ClearPoint® 2.0 software with live vo
Slide 16: Become the Premier Partner for Biologics and Drug Delivery
Part 2 Become the Premier Partner for Biologics and Drug Delivery Focused Resources for Branding, Device Development and Distribution No MRI Guidance © 2018 MRI INTERVENTIONS, INC. | 16
Slide 17: Become the Premier Partner for Biologics and Drug Delivery
Part 2 Become the Premier Partner for Biologics and Drug Delivery Focused Resources for Branding, Device Development and Distribution © 2018 MRI INTERVENTIONS, INC. | 17
Slide 18: Integrated Therapy Products Simplify Workflow
Integrated Therapy Products benefit the patient and hospital by simplifying workflow and making procedures more efficient and cost effective Adding therapy helps MRIC generate additional revenue per procedure
Slide 19: Initial Stroke Product (ClearPoint PURSUIT) Targets Intracerebral Hemorrhage
Initial Stroke Product (ClearPoint PURSUIT™) Targets Intracerebral Hemorrhage (ICH) • Collaboration with Mayo Clinic • Only major stroke subtype w/o clearly effective therapy – major unmet medical need • Affects 80,000 to 100,000 people in the US each year Current Approaches for Hemorrhage Removal a
Slide 20: Relocating Clinical Specialists closer to case clusters
Relocating Clinical Specialists closer to case ‘clusters’ to reduce travel • Hiring new specialists to locations where new placements are planned • Prioritize shorter procedure times so two cases are performed in the same day •
Slide 21: Manufacturing Facility in Irvine, CA
Manufacturing Facility in Irvine, CA • Current facility capable of producing 5x more product without expansion • Target gross margin expansion above 70% in next five years Global Strategy being prioritized based on adoption of partner therapies • SmartFlow® Cannulas is now CE Mark Approved and will
Slide 22: Cash Flow From Operations: 2015 - 2018
Cash Flow From Operations: 2015 - 2018 $- $(500,000) $(1,000,000) $(1,500,000) $(2,000,000) $(2,500,000) $(3,000,000) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Frcst Q3 Frcst Q4 Frcst 2015 2016 2017 2018
Slide 23: MRIC: Executive Summary
MRIC: Executive Summary • Unique, Platform technology enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders • Large, Growing installed base in 53 of 250+ leading Neurology centers in U.S. • Procedure volume has grown 43%+ CAGR from 2013-2017 •
MRI Interventions — Investor Presentation (September 2018) on 6ix